liveBook · Manning

Bioavailability

As explained in Build AI Drug Discovery Pipelines

Bioavailability is the fraction of an administered drug dose that reaches the circulatory system in an available form.

Bioavailability is the fraction of an administered drug dose that reaches the circulatory system in an available form. A candidate needs sufficient bioavailability to exceed the concentration required for therapeutic effect at its target. section 1.4.2

Delivery route and metabolism affect this metric: intravenously administered drugs generally have higher bioavailability than oral drugs, while metabolism can transform a therapeutic compound into a non-therapeutic form. section 1.4.2

Route and metabolism

Compare an intravenous medication with an oral counterpart, then consider whether metabolism alters the therapeutic compound before it becomes available at the target. section 1.4.2

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Defines the fraction reaching circulation and names delivery and metabolism as factors, without detailing measurement methods or pharmacokinetic models.
Examples
Uses intravenous-versus-oral delivery and metabolic transformation into a non-therapeutic form as examples.
What you can do after
Evaluate how delivery route and metabolism may affect whether a drug surpasses the concentration needed for therapeutic effect.
How it connects
Connects bioavailability with ADMET, absorption, metabolism, dosage, therapeutic effect, and drug delivery.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.